PARP1 and pancreatic neoplasm: As such, PARP inhibition may be effective in blocking the ERK signaling network or increasing activity of ERK/MEK inhibitors, agents already shown to be efficacious in acute myeloid leukemia, multiple myeloma, melanoma, colorectal, breast, lung, and pancreatic cancers (64–68).